NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
NCT00461747: Phase 3 - GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM